Evidence map›Paper›PMID 39402288›Full record

ArticleMedical oncology (Northwood, London, England)2024

Pancancer analysis of NDUFA4L2 with focused role in tumor progression and metastasis of colon adenocarcinoma.

Runlong Zhou, Zhe Sun, Ruijie Zhou, Mengyi Wang, Qing Zhuo, Xiaotong Deng, Zhenrong Wang, Yao Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Runlong Zhou *Institute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China.
Zhe Sun *College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.
Ruijie ZhouInstitute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China.
Mengyi WangInstitute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China.
Qing ZhuoInstitute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China.
Xiaotong DengInstitute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China.
Zhenrong WangInstitute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China.
Yao XuInstitute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430081, Hubei, China. xuyao0307@wust.edu.cn.

Funding

Foundation of Hubei Province Supporting Enterprise Technology Innovation Development 2021BAB126Wuhan East Lake High-tech Zone "JieBangGuaShuai" Project 2022KJB113
6 · The paper itself

Abstract

Colon adenocarcinoma (COAD) is a prevalent gastrointestinal malignant disease with a high mortality rate, and identification of novel prognostic biomarkers and therapeutic targets is urgently needed. Although NDUFA4L2 has high expressions in various tumors and affects tumor progression, its role in COAD remains unclear. The role of NDUFA4L2 in COAD was analyzed utilizing datasets available from public databases including The Cancer Genome Atlas, The Genotype-Tissue Expression (GTEx), Gene Expression Omnibus, Alabama Cancer Database (UALCAN), and The Human Protein Atlas databases. The prognostic value of NDUFA4L2 was determined using Kaplan-Meier analysis and Cox regression analysis. To investigate the possible mechanism underlying the role of NDUFA4L2 in COAD, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were employed. The correlation between NDUFA4L2 expression and immune cell infiltration levels was examined through single-sample gene set enrichment analysis (ssGSEA). The NDUFA4L2 expression levels in COAD patients and cell lines were validated through immunohistochemistry, immunofluorescence, qRT-PCR, and Western blot. Wound healing assay was also performed to evaluate the effect of NDUFA4L2 on COAD metastasis. Furthermore, the NDUFA4L2 mediated competing endogenous RNA (ceRNA) regulatory network was predicted and constructed through a variety of databases. The comprehensive pan-cancer analysis showed that NDUFA4L2 possesses diagnostic and prognostic value in many cancers, especially in COAD. GO-KEGG and GSEA analyses indicated that NDUFA4L2 was associated with multiple biological functions including epithelial-mesenchymal transition and adaptation to hypoxia. The ssGSEA analysis showed that NDUFA4L2 expression was associated with immune infiltration. In vitro experiments confirmed upregulation of NDUFA4L2 in COAD tissues and cell lines, and NDUFA4L2 overexpression significantly promoted migration of COAD cells. In addition, the C9orf139 /miR-194-3p axis was speculated as the possible upstream regulators of NDUFA4L2 in COAD. This study demonstrated that NDUFA4L2 upregulation was correlated with tumor progression, relapsed prognosis and aggressive migration of COAD, suggesting that NDUFA4L2 can act as an effective prognostic biomarker and a promising therapeutic target for COAD treatment.

Indexed as

AdenocarcinomaColonic NeoplasmsDisease ProgressionElectron Transport Complex IBiomarkers, TumorCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisPrognosisBiomarkers, TumorElectron Transport Complex INDUFA4L2 protein, humanColon adenocarcinomaImmune infiltrationNDUFA4L2PrognosisTumor migration

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.